

REVERSE DOSIMETRY IN TKPLATE TO RECONSTRUCT EXPOSURE DISTRIBUTIONS USING BIOMONITORING DATA

Jean Lou CM Dorne, Lead expert in NAMs

Jose Cortinas-Abrahantes, Alicia Paini

Senior Scientific Officers

Keyvin Darney, ANSES, Senior Scientific Officer

OUTLINE

TKPlate 1.0 : Introduction and General Workflow

TKPlate : Reverse Dosimetry

Caffeine Case Study

Current and Future perspectives






TKPlate General Workflow and Reverse Dosimetry



TKPLATE 1.0: INFO PAGE AND GENERAL WORKFLOW



The screenshot shows the TKPlate 1.0 web application interface. The browser address bar displays the URL <https://r4eu.efsa.europa.eu/app/tktd>. The page header includes the EFSA logo and the title "TKPlate Interactive Modelling Platform". A navigation menu at the top lists various modules: Info, Input, Forward Dosimetry, Reverse Dosimetry, Toxicodynamic, DEB, MixTox, and Report. The main content area features a "WELCOME TO TKPLATE" section, followed by a description of the tool as an open-source platform for PBK models and NAMs. A list of references is provided, including a 2020 publication by EFSA. An overview section follows, detailing the three main modules: Input, Forward Dosimetry, and Reverse Dosimetry.

WELCOME TO TKPLATE

This tool is EFSA's open source platform for the use of physiologically-based kinetic (PBK) models and New approach methodologies (NAMs) in human health, animal health and environmental risk assessment of chemicals. For more technical information, see:

- EFSA (European Food Safety Authority), Bossier H, Chau J, Cheikh N, Varewyck M, Verbeke T and Vergucht S. 2020 A Web-based open source tool for Toxicokinetic and Toxicodynamic modelling. EFSA supporting publication 2020:EN-1926. 25 pp [doi:10.2903/sp.efsa.2020.EN-1926](https://doi.org/10.2903/sp.efsa.2020.EN-1926)


After 10 minutes of inactivity the app will stop working.

OVERVIEW

This info page is intended to give a quick overview of some of the possibilities within TKPlate. More details and information can be consulted in the [User Manual](#). The following sections describe the different modules that are available within the TKPlate 1.0 platform.

1. The first module [**Input**] is the module where most input parameters must be provided. These are predominantly used for the forward dosimetry and benchmark dose modelling sections. Some parameter specific inputs such as biomonitoring data require uploading be uploaded in the modules requiring these data.
2. The second module [**Forward Dosimetry**] is performing forward dosimetry where concentrations of chemicals in target organs of species are calculated after being exposed to an external dose. Variability is taken into account by means of Monte Carlo stochastic simulations. This module also provides the options to perform sensitivity analysis, check empirical data and compare different simulation results.
3. The third module [**Reverse Dosimetry**] provides a means to perform reverse dosimetry which is used to predict a plausible exposure from bio-monitoring data.

TKPlate Workflow



RELEVANCE OF TKPLATE 1.0 TO EFSA'S REMIT

❖ Relevance to EFSA

- All Units dealing with chemicals at EFSA
- Supports use of NAMs@EFSA without testing: generate TK TD profiles, Id data gaps etc..
- Pesticides, food and feed additives, contaminants, novel foods etc.
- PBK/QIVIVE particularly relevant to pesticides (e.g. Developmental Neurotoxicity).

❖ Input parameters

- Data from regulatory dossiers (i.e. kinetic data/dose response data for regulated products)
- Data from literature
- Previous assessments
- Public databases such as EFSA's OpenFoodTox, US-EPA CompToxChemicals dashboard, ECHA's REACH Database



WHAT CAN TKPLATE 1.0 DO FOR RISK ASSESSMENT AS A NAM TOOL ?

- ❖ **Human and animal PBK models in Annex of 2021 OECD guidance, described/validated with reporting template**
- ❖ **Forward Dosimetry (From exposure to internal dose) for humans and animals (test/farm)**
 - Predict through simulations elimination and residues of chemicals in blood/target organs:
 - ✓ In vivo data (oral route as well as multiple route (oral, dermal, inhalation))
 - ✓ In vitro data through QIVIVE models
 - Comparison predictions/ experimental data for kinetic profiles/ residues in fluids/organs
 - Inter-species comparisons
- ❖ **Reverse Dosimetry (From internal to external dose)**
 - Recalculate exposure based on biomonitoring data
 - Can be used to derive human biomonitoring guidance values (HBM-GVs) i.e. assess chemical exposure levels measured in HBM studies in a health risk assessment context.



TK PLATE 1.0 : PUBLICATION AND ASSOCIATED OUTPUTS

Further development of a web-based open-source platform for Toxicokinetic and Toxicodynamic modelling: TKPlate 1.0

Han Bossier, Joris Chau, Machteld Varewyck, Stephanie Vergucht and Tobias Verbeke

Open Analytics NV

Technical Report

APPROVED: 8 November 2023
doi: 10.2903/sp.efsa.2023.EN-8441



User Guide for TKPlate 1.0: An open access platform for implementing new approach methodologies in chemical risk assessment through toxicokinetic and toxicodynamic modelling

European Food Safety Authority (EFSA),
Han Bossier, José Cortiñas-Abrahantes, Keyvin Darney, Fotis Spyropoulos,
Leonie S Lautz, Pierre André Billat, Rémy Beaudouin, Florence Zeman, Cléo
Bodin, Jean Lou CM Dorne

Approved: 12 October 2023
DOI: 10.2903/j.efsa.2023.e211101

EDITORIAL

efsa JOURNAL

TKPlate 1.0: An Open-access platform for toxicokinetic and toxicodynamic modelling of chemicals to implement new approach methodologies in chemical risk assessment

Technical Report

APPROVED: 8 November 2023
doi: 10.2903/sp.efsa.2023.EN-8440



Applications of TKPlate 1.0 for toxicokinetic and toxicodynamic modelling of chemicals: Case Studies

European Food Safety Authority (EFSA),
Han Bossier, Fotis Spyropoulos, Keyvin Darney, Leonie S Lautz, Pierre André
Billat, Rémy Beaudouin, Florence Zeman, Cléo Bodin, José Cortiñas-
Abrahantes, Jean Lou CM Dorne






TKPlate: Reverse Dosimetry



REVERSE DOSIMETRY MODULE : WHAT THE BODY DOES TO THE CHEMICAL : FROM THE INSIDE TO THE OUTSIDE



Predicting human exposure from concentrations inside the body (blood or urine levels): Biomonitoring



INTRODUCTION TO REVERSE DOSIMETRY

- **Definition:** Reconstruct exposure distribution from internal measured concentrations
- **Key Purpose:** Allows more accurate interpretation HBM data identifying external exposure sources.
- **Example:** Select kinetic/PBK model to simulate external dose for a given exposure scenario

The screenshot displays the TKPlate Interactive Modelling Platform interface, specifically the 'Reverse Dosimetry' tab. The interface is divided into several sections:

- Header:** Includes the 'efsa' logo, the title 'TKPlate Interactive Modelling Platform', and version information 'v 1.0.23 - Manual - Report new issue'.
- Navigation:** A horizontal menu with tabs: 'Info', 'Input', 'Forward Dosimetry', 'Reverse Dosimetry' (active), 'Toxicodynamic', 'DEB', 'MixTox', and 'Report'.
- Sub-tabs:** Under the 'Reverse Dosimetry' tab, there are sub-tabs: 'Input Data', 'Posterior distribution', 'Time-concentration curves', and 'Analysis logs'.
- Biomonitoring data section:**
 - 'Selected model (Input tab):' set to 'pbtk1cpt'.
 - 'Select model compartment:' a dropdown menu showing 'Compartment'.
 - 'Time unit of measured data:' radio buttons for 'hour', 'min' (selected), and 'sec'.
 - 'Exposure time (same unit as above):' a text input field containing '0.5'.
- Markov Chain Monte-Carlo settings section:**
 - 'Choose prior distribution for exposed dose (mg/ kg BW / min):' a dropdown menu showing 'Truncated Normal'.
 - Parameters: 'Mean' (5), 'SD' (1000), 'min' (0), and 'max' (50).
 - 'Number of independent chains:' a slider set to 4.
 - 'For each chain, set number of:'
 - 'sampling iterations' (2000)
 - 'burn-in (i.e. discarded) iterations' (1000)
 - A checkbox for 'Use custom starting seeds'.
 - A '(Re-)run MCMC' button.
- Upload Data section:**
 - 'Upload Data' heading.
 - 'General Information' section with 5 numbered instructions for data upload.
 - 'Upload Data (CSV)' section with a 'Browse...' button (labeled 'No file selected'), a 'Clear data' button, and a 'Load fictional data' button.



STEPS IN REVERSE DOSIMETRY

1. **Select PBK Model:** Define set of input parameters (chemical-specific and physiological parameters) to simulate kinetic processes (select model)
2. **Biomonitoring Input:** Biomonitoring data (e.g., blood) measuring concentrations of chemicals, compartment of interest, exposure scenario and MCMC settings.
3. **Output:** Run simulations, diagnostic of model are presented, checking convergence and other metrics to support model evaluation. In addition, posterior distribution of the attributable external dose based on previous inputs as well as a plot of observed vs fitted biomonitoring data are provided.



STEPS IN REVERSE DOSIMETRY: PBPK MODEL AND PARAMETERS

1.1. PBPK Model inputs: Defining model type, species, chemical and exposure setting

Info **Input** Forward Dosimetry Reverse Dosimetry Toxicoc

Input

Model Type
Changing the model resets all filled-in parameter values.
1-compartment

Species
Changing the species resets all filled-in parameter values.
Human

Chemical
Available options for chemical selection
Melatonin
User Defined Chemical
☐ Show EPA CompTox Search URL

Exposure Settings

Dose unit
☐ g ☒ mg ☐ microg

Time unit
☐ d ☒ h ☐ min ☐ sec

Exposure Metric
☐ absolute (mg) ☐ dose (mg/kg BW) ☒ rate (mg/kg BW / h)

Magnitude of each input (mg / kg BW / h)
0

Timepoint of first input (h)
0

Exposure time (h) (Cannot be zero)
0.5

Single or multiple doses?
☒ Single
☐ Multiple

1.2. Chemical Specific and Physiological inputs:

Chemical Specific Parameters

	Parameter	Value	Unit	Descript
1	k_abs	2.18	min ⁻¹	Absorption rate constant
2	ke	0.23	min ⁻¹	Elimination rate constant
3	MW	232.3	g/mol	Molecular weight
4	vdist	1.1	L/kg	Volume of distribution

Physiological Parameters

	Parameter	Value	Unit	Descript
1	BW	70	kg	Body weight



STEPS IN REVERSE DOSIMETRY: BIOMONITORING INPUT

2.1. Model and Compartment

Selected model (Input tab):
pbtk1cpt

Select model compartment
Ccompartment

2.3. MCMC setting

Markov Chain Monte-Carlo settings

Choose prior distribution for exposed dose (mg/ kg BW / min)
Truncated Normal

Mean: 5 SD: 1000 min: 0 max: 50

Number of independent chains:
4

For each chain, set number of:
sampling iterations: 2000 burn-in (i.e. discarded) iterations: 1000

☐ Use custom starting seeds.

(Re-)run MCMC!

2.2. Upload Biomonitoring data






Once everything is uploaded and select, run the MCMC procedure



STEPS IN REVERSE DOSIMETRY: OUTPUT

3.1. Model diagnostic

Diagnostics



How to interpret the diagnostic plots?

Trace-plot:
Shows you the sampled value for dose for each iteration.
You would like to see trace-plots where the chains seem to
1) converge to a range (i.e. they stabilize)
2) visit the entire range of the resulting posterior distrib

Trimmed trace-plot:
Using the left trace-plot, one can determine if enough iterations
discarded (i.e. the burn in) or too many of them are discarded.
See it yourself: adjust the burn in on the left and see what

Autocorrelation:
Due to the nature of the sampling algorithm, there should be
a high correlation between iterations within a chain.
However as we compare more distant iterations (i.e. increase
we should see the correlation going to 0.

If there seems to be a problem with any of these, try to:
* increase the number of chains
* increase the number of iterations per chain

Complete MCMC runs for 4 chains representing different starting points

Trimmed MCMC runs after burn-in is discarded for the 4 chains, providing information about convergence and mixing of each chain


Autocorrelation plot showing how well the chains are mixing, with low autocorrelation indicating good mixing and convergence is achieved



STEPS IN REVERSE DOSIMETRY: OUTPUT

3.2. Posterior distribution of external dose

Density (trimmed chains)



Summary of posterior of dose (over all chains):

Min.	1st Qu.	Median	Mean	3rd Qu.	Max.
9.783	10.046	10.134	10.132	10.212	10.561

- Two plots are shown, one showing the posterior distributions for each chain separately and the second one with all chains combined.
- Summary statistics of posterior distribution indicating that in this case the potential external dose is around 10.1, with a minimum of 9.7 and maximum of 10.6





Caffeine Case Study



CAFFEINE PARAMETERS

Exposure Settings

Dose unit

☐ g ☒ mg ☐ microg

Time unit

☐ d ☒ h ☐ min ☐ sec

Exposure Metric

☒ absolute (mg) ☐ dose (mg/kg BW) ☐ rate (mg/kg BW / h)

Magnitude of each input (mg)

270

Timepoint of first input (h)

0

Exposure time (h) (Cannot be zero)

0.01

Single or multiple doses?

☒ Single

☐ Multiple

Time Scale

☒ Upload custom time points

time steps /h

4

Simulation duration (h)

32

In vitro/QIVIVE US-EPA Comptox data

CL_{int} = 0.2855 µL/min/million hepatocytes


- $CL_{in\ vivo} = 0.2855 \times 140 \text{ (million hepatocytes/g liver)} \times 2000 \text{ (g liver)} = 0,08 \text{ L/min}$ metabolism via CYP1A2
- Exposure **270 mg oral**
- Simulation with variability in CYP1A2 35% (Dorne et al., 2001)

Chemical Specific Parameters

	Parameter	Value	Unit	Description
1	BP	1		Blood plasma ratio
2	cl_hepatic	0.08	L/min	Hepatic clearance
3	frac_abs_gut	0.8		Fractional absorption gut
4	FUP	1		Fraction unbound in plasma
5	GFR	0.06	L/min	Glomerular filtration rate
6	k_abs	0.01	min ⁻¹	Absorption rate constant (1st order)
7	MW	194.2	g/mol	Molecular Weight

8	P_adipose	0.263825		Blood tissue partition coefficient in the adipose
9	P_gut	0.943705		Blood tissue partition coefficient in the gut
10	P_kidney	1.025077		Blood tissue partition coefficient in the kidney
11	P_liver	1.013832		Blood tissue partition coefficient in the liver
12	P_rapid	1.002098		Blood tissue partition coefficient in the rapid compartment
13	P_slow	0.984071		Blood tissue partition coefficient in the slow compartment


Caffeine Forward Dosimetry



	0%-quantile	2.5%- quantile	50%-quantile	97.5%- quantile	100%-quantile
T-max (h)	2.50E+00	2.74E+00	3.00E+00	3.50E+00	3.75E+00
C-max (mg/L)	2.67E+00	2.95E+00	3.66E+00	4.73E+00	5.19E+00
Half-life (h)	5.00E+00	6.00E+00	8.00E+00	1.08E+01	1.20E+01
AUC (h * mg/L)	2.90E+01	3.49E+01	4.44E+01	5.36E+01	5.78E+01



Caffeine : Model Evaluation Predictions vs Experimental Data




Lelo et al., (1986) doi.org/10.1111/j.1365-2125.1986.tb05246.x




CAFFEINE— FORWARD DOSIMETRY

MC simulated trajectory

Median, lower-2.5% and upper 97.5% quantiles, pointwise in time




Predicted vs observed concentrations.




CAFFEINE – REVERSE DOSIMETRY

Using Caffeine time concentration profiles (Lelo et al., 1986) to recalculate exposure: reverse dosimetry
Satisfactory redictions: Exposure 270 mg oral-Reverse dosimetry prediction median : 250 mg



	Min	Q1	Median	Q3	max
Dose (mg)	228	246	250	255	286



New Human and animal models

- Pregnancy/Gestational models
- Ontogenesis of enzymes
- Generic models for metabolites (detoxification/bioactivation)
- Reverse dosimetry models for metabolites/HBM/urine etc
- Bioaccumulation models (EFSA/ECHA)

Animal models

- Physiologically-based for cats, minipig, goat, turkey etc
- PBK/DEB models for salmon
- Web TKTD Tool to assess effect of pesticides on bird reproduction

ERA models

- Generalise DEB and TKTD models across species



CONCLUSION AND FUTURE PERSPECTIVES



▪ TKPlate and Reverse dosimetry Training

- Reverse dosimetry models providing outputs for blood
- Need to include urine, parent compound and metabolites, other organs

TKPlate Training


- Pilot planned for EFSA Staff and experts on 21-22 Nov 24 and Jan 25
- Moving towards recorded online training available open access ?

▪ Moving towards application of TKPlate in EFSA panels

- Differences in NAM across EFSA panels: regulations, history
- Change management may be needed: from in vivo to NAMs

▪ EC/International collaborations

- PARC/ASPIS EU : follow up on models and data developed, uptake TKPlate
- Future APRCA case study on use of TKPlate for QIVIVE ?



ACKNOWLEDGEMENTS

- EFSA Staff: Jose Cortinas-Abrahantes, Fotios Spyropoulos, Djien Liem, Tobin Robinson, Georges Kass, Antony Smith, Jochem Louisse, Didier Verloo, Claudia Roncancio-Peña, Daniela Maurici, EFSA Senior Management
- Hans Bossier and Tobias , Open Analytics, Antwerp, Belgium
- Keyvin Darney, ANSES, Paris
- Leonie Lautz, Wageningen Agricultural Research Center, The Netherlands
- INERIS, Paris, France
- University of Utrecht, The Netherlands;
- ISS, Rome, Italy
- CERTARA Paris, London;
- Radboud University, Nijmegen, The Netherlands;
- Mario Negri, Milan, Italy
- RIVM, Bilthoven, The Netherlands
- Health and Safety Laboratory, UK
- US-EPA/NIEHS, USA





STAY CONNECTED

SUBSCRIBE TO

efsa.europa.eu/en/news/newsletters

efsa.europa.eu/en/rss

[Careers.efsa.europa.eu](https://careers.efsa.europa.eu) – job alerts



FOLLOW US ON TWITTER

[@efsa_eu](https://twitter.com/efsa_eu)

[@methods_efsa](https://twitter.com/methods_efsa)

[@plants_efsa](https://twitter.com/plants_efsa)

[@animals_efsa](https://twitter.com/animals_efsa)



FOLLOW US ON INSTAGRAM

[@one_healthenv_eu](https://www.instagram.com/one_healthenv_eu)



LISTEN TO OUR PODCAST

Science on the Menu – Spotify, Apple Podcast and YouTube



FOLLOW US ON LINKEDIN

[Linkedin.com/company/efsa](https://linkedin.com/company/efsa)



CONTACT US

efsa.europe.eu/en/contact/askefsa

